Publications

Berger K, Rossi G, Orlando V, Fabry P, Jensen IS, Gallacher ME, et al. Mobilizing stem cells with plerixafor in MM patients: Impact on a health care provider’s budget in Germany and Italy. 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 2017.

Jensen IS, Wu E, Sacks N, Cyr P, Chung K. 2017. Budget impact analysis of CPX-351 in the treatment of patients with treatment-related acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (MRC) from a US payer perspective. Blood 130(Sup 1):5615; 10.1182/blood.V130.Suppl_1.5615.5615.

Thompson C, Rager J, Suh M, Proctor D, Haws L, Harris M. Mechanistic support for nonlinear risk assessment of rat oral cavity tumors induced by exposure to Cr(VI) in drinking water. Poster presented at 56th Society of Toxicology Annual Meeting. March 15, Baltimore, MD, March 2017.

Suh M, Harvey S, Wikoff D, Mittal L, Ring C, Goodmanson A, Proctor D. Meta-analysis of hexavalent chromium and stomach cancer. Poster presented at Society of Toxicology 56th Annual Meeting, March 13, Baltimore, MD, March 2017.

Lowe KA, Danese MD, Gleeson ML, Langeberg WJ, Kelsh MA. 2016. Racial and ethnic variability in the prevalence and incidence of comorbidities associated with gastric cancer in the United States. J Gastrointest Cancer 47(2):168–181; doi: 10.1007/s12029-016-9809-5.

Kelsh MA. Evaluating biosimilars in observational data: Some methodological considerations. Presented at International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland, August 25–28, 2016.

Young L, Sacks N, Cyr PL, Sharma A, Dahdal DN. Rates of hospitalization and repeat procedures in patients receiving sodium picosulfate/magnesium citrate bowel preparation prior to colonoscopy. Academy Managed Care Pharmacy Annual Meeting, San Francisco, CA, 2016. Bronze Medal Winner.

Lancet JE, Sacks NC, Cyr PL, Chiarella MT, Louie AC, Cortes JE. VYXEOS™ (CPX-351) increases event-rree survival and time spent out of the hospital in acute myeloid leukemia patients, compared with 7+3 standard of care. Academy of Managed Care & Specialty Pharmacy Annual Meeting, San Francisco CA, April 2016.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. Hospitalizations for older patients with acute myeloid leukemia (AML): High costs and long stays, with and without chemotherapy. Academy Health Annual Research Meetings, Boston, MA, 2016.

Sacks NC, Cyr P, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. Blood 128(22):4780; doi: 10.1182/blood.V128.22.4780.4780.